Generic drugs must meet the same quality criteria and safety profiles as the original drugs. The strictest tests in accordance with international guidelines prove the same quality, safety and bioavailability of every single generic drug.
In Austria, the share of generics in the generics-capable market is 59 percent. This refers to the market in which there is a corresponding generic drug for an original drug.
In Austria, Austrians received 13 million packages of Genericon drugs in 2023.
In contrast to so-called original drugs, the production of a generic drug is much faster and cheaper, since the active ingredient has already been used in therapy for years and has proven to be very effective. As a result, generic drugs can be offered at significantly lower prices.
After generic drugs contain the same active ingredient as the original drug and the same efficacy has been proven by bioequivalence studies, the generic drug behaves in the body in the same way as the original drug. This equality applies to both efficacy and safety. There are also no differences between the original drug and the generic drug in the quality requirements for drugs and their manufacturers that are monitored by the authorities, such as the pharmaceutical quality assurance system or the analysis and release of each batch of a drug.
A bioequivalence study is a comparative bioavailability study. Bioavailability is the extent and speed of drug absorption from a dosage form into the circulation and thus the availability of the drug at the site of action. This internationally recognised procedure is used to prove whether bioequivalence (same bioavailability) exists between a generic drug and the original drug.
Differences in composition between a generic product and the original medicinal product are only permitted for excipients (fillers, colours, etc.) but not for active ingredients. For example, corn starch can be used as an excipient instead of lactose. However, these differences must not have any demonstrable influence on the therapeutic effect or on the behaviour of the medicinal product in the body.
Doctors prescribe Genericon for various reasons. Genericon drugs are often offered in a larger package size than the original drugs. This results in a savings effect for patients on the prescription fee to be paid. In addition, the prescription is considerably simplified for special indications. As a result, more patients are treated with a drug with proven bioequivalence galenics that has been tried and tested over many years. This enables doctors to handle the contributions of the insured with care and also has a decisive effect on increasing the quality of care. We offer very special combination preparations which increase the adherence to therapy and reduce the prescription fees of the patients.
Generics from Genericon can largely be identified by their two-part name. Here, the active ingredient and the company name "Genericon" are given as the name. For example, "Ambroxol Genericon" soluble tablets: "Ambroxol" is the active ingredient and "Genericon" is the company name.
The decisive feature of Genericon's quality drugs is the dolphin on the package. The dolphin with its high recognition value stands for sympathy, quality, trust and safety.
